Homoharringtonine as a Rapid SARS-CoV-2 Antiviral: New Evidence

Study Background and Research Question

The COVID-19 pandemic underscored the urgent need for broadly effective antiviral interventions, especially for respiratory infections caused by coronaviruses. While vaccines and direct-acting antivirals have provided essential tools, the rapid emergence of new variants and the risk of future epidemics demand additional strategies. Homoharringtonine, a cytotoxic alkaloid originally derived from Cephalotaxus hainanensis and used in hematological malignancy research, has gained attention for its mechanism as a protein synthesis inhibitor. The reference study (Wen et al., 2025) investigates whether homoharringtonine can serve as a rapid, scalable antiviral agent against SARS-CoV-2, potentially clearing the virus from the upper respiratory tract (URT) and limiting community transmission early in infection.

Key Innovation from the Reference Study

This study introduces a unique application of homoharringtonine—previously established in leukemia research—for antiviral use against SARS-CoV-2. Exploiting the compound's ability to bind the eukaryotic 80S ribosome and inhibit protein chain elongation, the team hypothesized that viral replication could be suppressed at nanomolar concentrations. The core innovation lies in demonstrating that homoharringtonine, when administered locally (via nasal spray or nebulization), can rapidly reduce and even clear SARS-CoV-2 viral load from the URT in both preclinical and clinical contexts. This approach leverages the drug’s established pharmacodynamics while addressing the practical need for early-stage, non-systemic antiviral interventions during outbreaks (reference).

Methods and Experimental Design Insights

Wen et al. designed a multi-phase investigation integrating in vitro, animal model, and early clinical trial data:

• In vitro assays: Homoharringtonine was tested against four coronaviruses (including SARS-CoV-2) in cell culture models. Viral replication was quantified post-treatment at nanomolar concentrations, assessing the compound's potency as a protein synthesis inhibitor.
• Animal models: Mice were infected with SARS-CoV-2 and treated with daily nasal dripping of homoharringtonine (40 μg). Viral clearance from the URT was measured over a 3-day period.
• Clinical trials: In December 2022, twenty-six cancer patients received 1 mg/day homoharringtonine by nebulization. Viral load in the URT was measured 6 hours post-administration, with follow-up assessments. In May 2023, an additional cohort of eleven patients without major comorbidities received repeated nasal spray administration (total daily dose: 0.2 mg).

The multi-level design allowed the researchers to correlate molecular mechanism with organismal and clinical outcomes, providing a robust translational workflow.

Core Findings and Why They Matter

Key results from the study include:

• Potent in vitro inhibition: Homoharringtonine suppressed replication of all tested coronaviruses at nanomolar concentrations, supporting its broad-spectrum antiviral activity via protein synthesis inhibition (reference).
• Rapid in vivo viral clearance: In animal models, daily nasal administration resulted in complete SARS-CoV-2 clearance from the URT within 3 days in all treated mice.
• Human translational evidence: Among cancer patients treated by nebulization, average viral load in the URT decreased by three-quarters within 6 hours. In the healthy patient cohort using repeated nasal spray, 10 of 11 subjects cleared the virus in 2–4 days, which is significantly faster than the 7–9 day median observed in large national cohorts.
• Tolerability: No adverse effects were detected in either clinical trial subset.

These findings not only validate homoharringtonine’s mechanism as a protein synthesis inhibitor but also suggest that local administration may overcome systemic toxicity concerns, supporting its role as a first-line defense for future coronavirus epidemics.

Comparison with Existing Internal Articles

The translational arc seen in this new study aligns with and extends insights from prior reviews of homoharringtonine’s cross-domain potential. For instance, "Homoharringtonine: Cytotoxic Alkaloid for Cancer and SARS-CoV-2 Research" summarizes its efficacy in both leukemia and antiviral workflows, emphasizing rapid nanomolar-range activity. Similarly, another article highlights the compound’s capacity to clear SARS-CoV-2 from the URT, underscoring translational relevance. The new study adds clinical context with comparative cohort data and direct evidence of rapid viral clearance in humans, bridging an important data gap identified in previous literature. Workflow-focused articles, such as "Homoharringtonine: Cytotoxic Alkaloid Workflows in Cancer & Virology", have also discussed practical considerations for using APExBIO’s homoharringtonine in laboratory settings, which are now reinforced by the demonstrated efficacy and tolerability documented in the reference study.

Protocol Parameters

• In vitro antiviral assays: Employ homoharringtonine at nanomolar concentrations; titrate based on cell type and viral load, referencing the rapid suppression achieved in the reference study.
• Animal model administration: Daily nasal dripping at 40 μg per mouse for up to 3 days; monitor viral titers in upper respiratory samples.
• Clinical translation (pilot context): For aerosol/nasal delivery, daily dosing of 0.2–1 mg homoharringtonine may achieve rapid URT viral clearance, but larger trials are needed to optimize safety and efficacy.
• Compound handling: Due to water insolubility, dissolve in ethanol or DMSO (see product information); store at -20°C for maximal stability.

Limitations and Transferability

Despite promising results, several limitations warrant attention:

• Population size: The clinical trials described involved relatively small cohorts, limiting generalizability.
• Patient selection: Most clinical trial participants were either cancer patients or individuals without significant comorbidities; broader safety and efficacy data are needed for diverse populations.
• Long-term safety: Systemic toxicity is a known concern for cytotoxic alkaloids. While localized administration showed no acute adverse effects, long-term safety in non-cancer populations requires further investigation.
• Viral evolution: The study focused on dominant strains at the time (e.g., Omicron), and efficacy against future divergent variants will need ongoing evaluation.

Why this cross-domain matters, maturity, and limitations

The repurposing of homoharringtonine from leukemia and cancer biology to antiviral research exemplifies a strategic cross-domain bridge. Its established mechanistic profile—ribosomal inhibition and cell cycle G1 phase arrest—is exploited to halt viral replication, offering a unified workflow for both oncology and infectious disease researchers. However, while early findings are compelling, the maturity of this approach for routine clinical use outside of research settings remains limited by the need for larger, controlled trials and more comprehensive safety data (reference).

Research Support Resources

Researchers interested in extending these findings can utilize Homoharringtonine (SKU N1504) from APExBIO for in vitro, animal model, or translational assay development. The compound’s well-characterized solubility and storage profile facilitate integration into both cancer biology and SARS-CoV-2 antiviral workflows. All handling should adhere to cytotoxic agent precautions, and use is strictly for research purposes only.